What is the best marker for inhaled corticosteroid safety?

Allergy and Asthma Proceedings

Volumn 26, Issue 2, 2005, Pages 89-93

  Derendorf, Hartmut ^a   Hochhaus, Guenther ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; DISKHALER; FLUNISOLIDE; FLUTICASONE PROPIONATE; HYDROCORTISONE; MARKER; STEROID; TRIAMCINOLONE ACETONIDE; TURBUHALER;

AREA UNDER THE CURVE; ASTHMA; BONE DENSITY; BONE DISEASE; CATARACT; CIRCADIAN RHYTHM; COMPARATIVE STUDY; CONFERENCE PAPER; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; EVALUATION; GROWTH DISORDER; HEMOCONCENTRATION; HUMAN; HYDROCORTISONE RELEASE; INCIDENCE; INHALATION; LYMPHOCYTE; MEASUREMENT; MONITORING; PARAMETER; SIDE EFFECT; STEADY STATE; TIME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; BIOLOGICAL MARKERS; HUMANS; HYDROCORTISONE;

EID: 20044374704     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: Past lessons and future issues. J Allergy Clin Immunol 112:S1-S40, 2003.
2. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 91(suppl A):22-28, 1997.
3. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 101:S440-S446, 1998.
4. Rohatagi S, Derendorf H, and Zech K. Risk-benefit value of inhaled corticosteroids: A pharmacokinetic/pharmacodynamic perspective. Chest 123:430S-431S, 2003.
5. Edsbacker S, and Brattsand R. Budesonide fatty-acid esterification: A novel mechanism prolonging binding to airway tissue. Review of available data. Ann Allergy Asthma Immunol 88:609-616, 2002.
6. Hochhaus G, Mollmann H, Derendorf H, and Gonzalez-Rothi RJ. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 37:881-892, 1997.
7. Krishnaswami S, Hochhaus G, and Derendorf H. An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. AAPS PharmSci 2:E22, 2000.
8. Meibohm B, Hochhaus G, Mollmann H, et al. A pharmacokinetic/ pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. J Pharmacokinet Biopharm 27:127-147, 1999.
9. Rohatagi S, Hochhaus G, Mollmann H, et al. Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids. Pharmazie 50:610-613, 1995.
10. Rohatagi S, Hochhaus G, Mollmann H, et al. Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 35:1187-1193, 1995.
11. Rohatagi S, Tauber U, Richter K, and Derendorf H. Pharmacokinetic/ pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone. J Clin Pharmacol 36:311-314, 1996.
12. Mollmann H, Wagner M, Krishnaswami S, et al. Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. J Clin Pharmacol 41:1329-1338, 2001.
13. Nelson HS, Stricker W, Casale TB, et al. A comparison of methods for assessing hypothalamic-pituitary-adrenal (HPA) axis activity in asthma patients treated with inhaled corticosteroids. J Clin Pharmacol 42:319-326, 2002.
14. Meibohm B, Hochhaus G, Rohatagi S, et al. Dependency of cortisol suppression on the administration time of inhaled corticosteroids. J Clin Pharmacol 37:704-710, 1997.
15. Tinkelman DG, Reed CE, Nelson HS, and Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 92:64-77, 1993.
16. Wald JA, and Jusko WJ. Corticosteroid pharmacodynamic modeling: Osteocalcin suppression by prednisolone. Pharm Res 9:1096-1098, 1992.
17. Meibohm B, Derendorf H, Mollmann H, et al. Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. Int J Clin Pharmacol Ther 37:367-376, 1999.